



THE BRITISH JOURNAL OF PSYCHIATRY

April 1996

Vol. 168

Editorials

- Schizophrenia, CATCH 22 and FISH. *K. C. Murphy and M. J. Owen* 397
Accident neurosis revisited. *R. Mayou* 399

Review Article

- Are SSRIs a cost-effective alternative to tricyclics? *M. Hotopf, G. Lewis and C. Normand* 404

Papers

- The Camden schizophrenia surveys. I. The psychiatric, behavioural and social characteristics of the severely mentally ill in an inner London health district. *C. A. Harvey* 410
The Camden schizophrenia surveys. II. High prevalence of schizophrenia in an inner London borough and its relationship to socio-demographic factors. *C. A. Harvey, C. Pantelis, J. Taylor, P. J. McCabe, K. Lefevre, P. G. Campbell and S. R. Hirsch* 418
Schizophrenic patients remember that an event has occurred, but not when. *L. Rizzo, J. M. Danion, M. van der Linden and D. Grangé* 427
The dimensions of schizophrenia phenomenology. Not one or two, at least three, perhaps four. *M. F. Lenzenweger and R. H. Dworkin* 432
Public education for community care. A new approach. *G. Wolff, S. Pathare, T. Craig and J. Leff* 441

- Residential care in hospital and in the community – quality of care and quality of life. *G. Shepherd, M. Muijen, R. Dean and M. Cooney* 448
A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. *P. Tyrer, B. Ferguson, C. Hallström, M. Michie, S. Tyrer, S. Cooper, R. Caplan and P. Barczak* 457
The Galway study of panic disorder. III. Outcome at 5 to 6 years. *D. O'Rourke, T. J. Fahy, J. Brophy and P. Prescott* 462
A typology of sub-clinical senescent cognitive disorder. *K. Ritchie, D. Leibovici, B. Ledésert and J. Touchon* 470
A magnetic resonance imaging study of white matter lesions in depression and Alzheimer's disease. *J. O'Brien, P. Desmond, D. Ames, I. Schweitzer, S. Harrigan and B. Tress* 477
The diagnosis and prevalence of hyperactivity in Chinese schoolboys. *P. W. L. Leung, S. L. Luk, T. P. Ho, E. Taylor, F. L. Mak and J. Bacon-Shone* 486
Confirmatory factor analysis of the fear questionnaire with social phobia patients. *B. J. Cox, J. D. A. Parker and R. P. Swinson* 497
Should amenorrhoea be necessary for the diagnosis of anorexia nervosa? Evidence from a Canadian community sample. *P. G. Garfinkel, E. L. P. Goering, C. Spegg, D. Goldbloom, S. Kennedy, A. S. Kaplan and D. B. Woodside* 500


continued p. ii

Published by The Royal College of Psychiatrists

ISSN 0007-1250

Now you can lift depression with the body in mind

Site-specific
'Cipramil'
addresses
four key
dimensions of
antidepressant
therapy:



Cipramil
citalopram

Specifically treating depression

Lundbeck

Research for a
better life

Abbreviated Prescribing Information

Presentation: 'Cipramil' tablets, PL 0458/0058, each containing 20mg of citalopram as the hydrobromide. 28 (OP) 20mg tablets £21.28.

Indications: Treatment of depressive illness in the initial phase and as maintenance against relapse/recurrence. **Dosage:** Adults: 20mg a day. Depending upon individual patient response, this may be increased in 20mg increments to a maximum of 60mg. Tablets should not be chewed, and should be taken as a single oral daily dose, in the morning or evening without regard for food. **Elderly:** 20mg a day increasing to a maximum of 40mg dependent upon individual patient response. **Children:** Not recommended. Restrict dosage to lower end of range in hepatic impairment. Dosage adjustment not necessary in cases of mild/moderate renal impairment. No information available in severe renal impairment (creatinine clearance <20ml/min). **Contra-indications:** Combined use of 5-HT agonists. Hypersensitivity to citalopram. **Pregnancy and Lactation:** Safety during human pregnancy and lactation has not been established. Use only if potential benefit outweighs possible risk. **Precautions:** Driving and operating machinery. History of mania. Caution in patients at risk of cardiac arrhythmias. Do not use with or within 14 days of MAO inhibitors: leave a seven day gap before starting MAO inhibitor treatment. **Drug Interactions:** MAO inhibitors (see Precautions). Use lithium and

tryptophan with caution. Routine monitoring of lithium levels need not be adjusted. Alcohol is not advised. **Adverse Events:** Most commonly nausea, sweating, tremor, somnolence and dry mouth. **Overdosage:** Symptoms have included somnolence, coma, sinus tachycardia, occasional nodal rhythm, episode of grand mal convulsion, nausea, vomiting, sweating and hyperventilation. No specific antidote. Treatment is symptomatic and supportive. Early gastric lavage suggested. **Legal Category:** POM 24.1.95. Further information available upon request. Product licence holder: Lundbeck Ltd, Sunningdale House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK7 8LF. 'Cipramil' is a trademark. © 1995 Lundbeck Ltd.

Date of preparation: May 1995

References

1. Hyttel J. XXII Nordiske Psykiater-Kongres, Reykjavik, 11 August, 1988: 11-21.
2. Eison AS et al. Psychopharmacology Bull 1990; 26 (3): 311-315.
3. Rosenberg C et al. Int Clin Psychopharmacol 1994; 9 (Suppl 1): 41-48.
4. Shaw DM et al. Br J Psychiatry 1986; 149: 515-517.
5. Bech P and Caldwell P. Int Clin Psychopharmacol 1992; 6 (Suppl 5): 45-54.
6. Sindrup SH et al. Ther Drug Monit 1993; 15: 11-17.
7. Van Harten J. Clin Pharmacokinet 1993; 24 (3): 203-220.

0495/CIP/501/019

The British Journal of Psychiatry

April 1996

Volume 168

No. 4

Editor Greg Wilkinson *Liverpool*

Senior Associate Editor

Alan Kerr *Newcastle upon Tyne*

Associate Editors

Sidney Crown *London*

Julian Leff *London*

Sir Martin Roth *Cambridge*

Sir Michael Rutter *London*

Peter Tyrer *London*

Editorial Advisers

Herschel Prins *Leicester*

Sir John Wood *Sheffield*

Kathleen Jones *York*

Assistant Editors

Mohammed Abou-Saleh *Al-Ain*

Louis Appleby *Manchester*

German Berrios *Cambridge*

Alistair Burns *Manchester*

Patricia Casey *Dublin*

John Cookson *London*

David Cottrell *Leeds*

Nigel Eastman *London*

Tom Fahy *London*

Anne Farmer *Cardiff*

Michael Farrell *London*

Nicol Ferrier *Newcastle upon Tyne*

William Fraser *Cardiff*

Richard Harrington *Manchester*

Sheila Hollins *London*

Jeremy Holmes *Barnstaple*

Alexander Kellam *Cardiff*

Peter Kennedy *York*

Michael King *London*

Alan Lee *Nottingham*

Shôn Lewis *Manchester*

Robin McCreadie *Dumfries*

Ian McKeith *Newcastle upon Tyne*

Roy McClelland *Belfast*

Stuart Montgomery *London*

David Owens *Leeds*

Ian Pullen *Edinburgh*

Rosalind Ramsay *London*

Henry Rollin *London*

Jan Scott *Newcastle upon Tyne*

Mike Shooter *Cardiff*

Andrew Sims *Leeds*

Jeanette Smith *Bristol*

George Stein *London*

David Tait *Perth*

Corresponding Editors

Sidney Bloch *Australia*

Patrice Boyer *France*

J.M. Caldas de Almeida *Portugal*

Andrew Cheng *Taiwan*

Andrei Cristian *Romania*

E. L. Edelstein *Israel*

Václav Filip *Czech Republic*

Heinz Katschnig *Austria*

Kenneth Kendler *USA*

Toshi Kitamura *Japan*

Arthur Kleinman *USA*

F. Lieh Mak *Hong Kong*

Jair Mari *Brazil*

Harold Merskey *Canada*

Paul Mullen *Australia*

Ahmed Okasha *Egypt*

Volodymer Poltavetz *Ukraine*

Michele Tansella *Italy*

Toma Tomov *Bulgaria*

John Tsiantis *Greece*

J. L. Vázquez-Barquero *Spain*

Richard Warner *USA*

Statistical Adviser

Pak Sham *London*

Staff

Publications Manager

Dave Jago

Scientific Editor

Lesley Bennun

Deputy Scientific Editor

Aliki Buhayer

Assistant Scientific Editor

Dinah Alam

Editorial Assistants

Judy Ashworth

Julia Burnside

Marketing Assistant

Dominic Bentham

Past Editors

Eliot Slater 1961–72 Edward H. Hare 1973–77 John L. Crammer 1978–83 Hugh L. Freeman 1984–93

Founded by J. C. Bucknill in 1853 as the *Asylum Journal* and known as the *Journal of Mental Science* from 1858 to 1963

Published by the Royal College of Psychiatrists

Contents continued from front cover

Abnormal electroretinogram in cocaine-dependent patients – relationship to craving. *M. Roy, D. A. Smelson and A. Roy* 507

The use of environmental strategies and psychotropic medication in the management of delirium. *D. J. Meagher, D. O'Hanlon, E. O'Mahony and P. R. Casey* 512

Successful treatment of tardive dystonia with clozapine and clonazepam. *J. Shapleske, A. P. McKay and P. J. McKenna* 516

Columns

Correspondence 519

A hundred years ago 523

Book reviews 524

American Journal of Psychiatry (contents) 527

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists (a registered charity, registration number 228636). The *BJP* publishes original work in all fields of psychiatry. All communications, including manuscripts for publication, should be sent to the Editor, *British Journal of Psychiatry*, 17 Belgrave Square, London SW1X 8PG.

Full instructions to authors are given at the beginning of the January and July issues.

Subscriptions

Non-members of the College should contact the Publications Subscription Department, Royal Society of Medicine Press Limited, PO Box 9002, London W1A 0ZA (tel. 0171 290 2928; fax 0171 290 2929). Annual subscription rates for 1996 (12 issues post free) are as follows:

- Europe (& UK): institutions £160, individuals £140
- US: institutions \$310, individuals \$230
- Elsewhere: institutions £190, individuals £150
- Full airmail is £36/US\$64 extra.
- Single copies of the Journal are £14, \$25 (post free).

Payment should be made out to the British Journal of Psychiatry.

Queries from non-members about missing or faulty copies should be addressed within six months to the same address; similar queries from College members should be addressed to the Registration Subscription Department, The Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG.

© 1996 The Royal College of Psychiatrists. Unless so stated, material in the *British Journal of Psychiatry* does not necessarily reflect the views of the Editor or the Royal College of Psychiatrists. The publishers are not responsible for any error of omission or fact.

Next month in the *BJP*

Cytochromes and psychotropic drug interactions. *D. Taylor and M. Lader*

'Audible thoughts and 'Speech defect' in schizophrenia. A note on reading and translating Bleuler. *T. Szasz*. Commentaries by *Sir Martin Roth, A. Kerr and P. Howorth*

Patients' views towards care received from psychiatrists. *D. A. Barker, S. S. Shergill, I. Higginson and M. W. Orrell*

Mass hysteria: one syndrome or two? *A. Ali-Gombe, E. Guthrie and N. McDermott*

Demographic and obstetric risk factors for postnatal psychiatric morbidity. *R. Warner, L. Appleby, A. Whitton and B. Faragher*

Back issues

Back issues published before 1995 may be purchased from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent (tel. 01303 850 101).

Advertising

Correspondence and copy should be addressed to Peter T. Mell, Advertising Manager, PTM Publishers Ltd, 282 High Street, Sutton, Surrey SM1 1PQ (tel. 0181 642 0162; fax 0181 643 2275).

US Mailing Information

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists. Subscription price is \$295. Second class postage paid at Rahway, NJ. Postmaster send address corrections to the *British Journal of Psychiatry*, c/o Mercury Airfreight International Ltd Inc., 2323 Randolph Avenue, Avenel, New Jersey 07001.

©™ The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences – Permanence of Paper for Printed Library Materials. ANSI Z39.48–1984.

Typeset by Dobbie Typesetting Ltd, Tavistock, and Henry Ling Ltd.

Printed by Henry Ling Ltd, The Dorset Press, 23 High East Street, Dorchester, Dorset DT1 1HD.

CAMBRIDGE

Treatment of Anxiety Disorders

Clinician's Guide and Patient Manuals

G. ANDREWS, R. CRINO, C. HUNT, L. LAMPE and
A. PAGE

Provides clinicians with a review of the epidemiology, etiology, and evaluation of anxiety disorders, as well as manuals for conducting an effective cognitive behavioural programme for the common anxiety disorders. Offers a theoretical overview and a framework to help build successful treatment programmes.

£50.00 net HB 0 521 46521 4 438 pp. 1994

£22.95 net PB 0 521 46927 9

£14.95 net Treatment manuals 0 521 46958 9

Functional Psychiatric Disorders of the Elderly

Edited by E. CHIU and D. AMES

Foreword by TOM ARIE

The first comprehensive reference work and practical guide to address such disorders.

'this book is a joy to browse through, with stimulating coverage of functional psychiatric disorder ... providing solid and interesting reviews of all the main topics.'

Robert G Jones, *Journal of the Royal Society of Medicine*

£65.00 net HB 0 521 43160 3 640 pp. 1994

Dementia and Normal Ageing

Edited by F. A. HUPPERT, C. BRAYNE and
D. W. O'CONNOR

Foreword by E. S. PAYKEL

'... because of its many excellent chapters, updated references and cogent discussions the book should constitute a very informative and instructive reading for psychiatrists, gerontologists and psychologists. It can also be of interest to geneticists and sociologists, and be recommended as a comprehensive reference on aging and dementia to nurses, medical students and general practitioners.'

Neuropsychologia

£55.00 net HB 0 521 41393 1 590 pp. 1994

Brain Control of Responses to Trauma

Edited by N. J. ROTHWELL and
the late F. BERKENBOSCH

The first volume to look in depth at the way the brain responds to trauma and subsequently integrates and influences behavioural, metabolic, neurohumoral, cardiovascular and immune functions.

'a notable contribution.'

Sheila Jennett, *Journal of the Royal Society of Medicine*

£50.00 net HB 0 521 41939 5 352 pp. 1994

Psychosocial Processes and Health

A Reader

Edited by A. STEPTOE and J. WARDLE

Covers the influence of psychological and social factors on health and the development of illness.

'a useful reference for researchers in psychological medicine.' Adrian Furnham, *British Medical Journal*

£60.00 net HB 0 521 41610 8 537 pp. 1994

£24.95 net PB 0 521 42618 9

Community Psychiatry in Action

Analysis and Prospects

Edited by P. TYRER and F. CREED

Why is psychiatry turning towards the community?

By understanding the developments in this field from the research viewpoint, recent changes in practice are explained for the benefit of a range of individuals involved in the organisation of psychiatric care.

£27.95 net HB 0 521 47427 2 175 pp. 1995

Genius

The Natural History of Creativity

HANS EYSENCK

Professor Eysenck examines the nature of genius, and suggests what role factors such as intelligence, social status and gender play in its expression. The book will be required reading for psychologists, psychiatrists, philosophers and sociologists.

£37.50 net HB 0 521 48014 0 354 pp. 1995

£17.95 net PB 0 521 48508 8

Problems in the Behavioural Sciences

Now in paperback

Mental Health in Mental Retardation

Recent Advances and Practices

Edited by NICK BOURAS

'Practitioners in learning disability are recommended to read this book, which provides not only a broad perspective on the subject but also considerable practical help and advice as well.'

British Medical Journal

£19.95 net PB 0 521 55629 5 416 pp. 1995


Cambridge books are available from good bookshops, alternatively phone UK + 44 (0)1223 325970 to order direct using your credit card, or fax UK + 44 (0)1223 315052. For further information, please email Giulia Williams on science@cup.cam.ac.uk or browse our Worldwide Web server <http://www.cup.cam.ac.uk>



CAMBRIDGE
UNIVERSITY PRESS

The Edinburgh Building, Cambridge CB2 2RU

THE CONSTANT CURRENT
SERIES 5B E.C.T. APPARATUS



ECTONUS Constant Current Series 5B

Supplementing the Constant Current Series 5A ECT Apparatus

ECTONUS and ECTONUSTIM models available from the manufacturers with over 46 years of experience in the design of E.C.T. equipment.

ECTRON LTD

KNAP CLOSE LETCHWORTH HERTS ENGLAND SG6 1AQ
Telephone 01462 682124 Fax 01462 481463

Universities of Newcastle, Northumbria and
Sunderland & Newcastle City Health Trust

Two day conference
Longhirst Hall, Northumberland
June 20-21 1996

The Construction of Psychiatric Authority

Speakers to include:

Professor Thomas Szasz, State University of New York
Professor Alec Jenner, University of Sheffield
Professor Marius Romme, University of Limburg
Dr Mary Boyle, University of East London
Ron Coleman, Hearing Voices Network

Further information and application forms available from:
Dr Chris Stevenson, Dept. of Psychiatry, University of Newcastle,
Leazes Wing, Royal Victoria Infirmary, Queen Victoria Road,
Newcastle Upon Tyne, NE1 4LP
(0191) 232 5131 Ext. 25677, Fax. (0191) 227 5108



kidscape

TREATMENT DILEMMAS

A Joint Conference for Professionals Working
with Survivors of Childhood Sexual Abuse

Thursday, 6th June 1996

Allan Levy, QC—Legal Pitfalls for Professionals
Prof. Peter Fonagy & Dr Mary Target—Memory: Is
It Important?
Kay Toon—How Memories Break Through and
How You Deal With Them Therapeutically
Dr Geoff Brown—Child Abuse: The Major Problem
Facing Professionals Today
Marjorie Orr—Do Survivors Know Better than the
Professionals?

Venue: The Royal Geographical Society,
London SW7

Cost: £88.13 (inc. coffee, lunch & VAT)

KIDSCAPE, 152 Buckingham Palace Road,
London SW1W 9TR
Tel.: 0171 730 7300 Fax: 0171 730 7081

New Brief Pulse ECT with *Computer-Assisted* Easy Seizure Monitoring



Somatics Thymatron™ DGx

- Automatically monitors your choice of EEG-EEG, EEG-ECG, or EEG-EMG and determines EEG and motor seizure lengths.
- Computer-measured seizure quality, including postictal EEG suppression, seizure energy index.
- Up to 8 seconds stimulus duration; pulsewidth as short as 0.5 ms.
- Single dial sets stimulus charge by age; high-dose option available.
- FlexDial™ adjusts pulsewidth and frequency without altering dose.

Distributed in the U.K. by:
DANTEC Electronics, Ltd.
Garonor Way
Royal Portbury
Bristol BS20 9XE
TEL (44) 1275-375333
FAX (44) 1275-375336

Distributed in Australia by:
MEECO Holdings Pty. Ltd.
10 Seville St.
North Parramatta NSW 2151
Australia
TEL (61) 2630-7755
FAX (61) 2630-7365

Distributed in New Zealand by:
WATSON VICTOR, Ltd.
4 Adelaide Rd.
Wellington, New Zealand
TEL (64) 4-385-7699
FAX (64) 4-384-4651

Distributed in India by:
DIAGNO.SYS
New Delhi
TEL (91) 11-644-0546
FAX (91) 11-622-9229

Distributed in Pakistan by:
IQBAL & CO.
Islamabad
TEL (92) 51-291078
FAX (92) 51-281623

Distributed in South Africa by:
DELTA SURGICAL
Craighall
TEL (27) 11-792-6120
FAX (27) 11-792-6926

Distributed in U.S.A. and Canada by:


 **SOMATICS, INC., 910 Sherwood Drive # 17, Lake Bluff, IL, 60044, U.S.A.**
Fax: (847) 234-6763; Tel: (847) 234-6761

—EFEXOR—

THE WORLD'S FIRST

S · N · R · I

SEROTONIN NORADRENALINE REUPTAKE INHIBITOR



Source: www.nasa.gov (National Aeronautics and Space Administration, NASA)

The result of original Wyeth research and development, Efexor (venlafaxine) is the first of a new class of antidepressants, the SNRIs.

Efexor is a serotonin and noradrenaline reuptake inhibitor and increases the availability of both of the key neurotransmitters involved in depression.¹ This is in line with current thinking on the pathophysiology of depression, which stresses the importance of interactions between serotonin and noradrenaline.²

Extensive clinical trials of Efexor in over 2,500 depressed patients have confirmed the success of this approach. Efexor has been shown to be at least as effective and better tolerated than standard tricyclic and related antidepressants such as dothiepin, imipramine and trazodone.³

Efexor has also been shown to compare favourably with the SSRI fluoxetine in inpatient⁴ and outpatient studies.⁵ Furthermore, Efexor demonstrates a significant dose response curve which allows flexibility of treatment in a wide range of patients.⁶

For many depressed patients, the world's first SNRI could make a world of difference.




EFFECTIVE IN A WIDE RANGE OF DEPRESSED PATIENTS

PRESCRIBING INFORMATION PRESENTATION: Tablets containing 37.5mg, 50mg or 75mg venlafaxine (as hydrochloride). USE: Treatment of depressive illness. DOSAGE: Usually 75mg/day (37.5mg b.d.) with food, increasing to 150mg/day (75mg b.d.) if necessary in more severely depressed patients. 150mg/day (75mg b.d.) increasing every 2 or 3 days in up to 75mg/day increments to a maximum of 375mg/day, then reducing to usual dose consistent with patient response. Discontinue gradually. Elderly: use normal adult dose. Doses should be reduced by 50% for moderate renal or moderate hepatic impairment. CONTRA-INDICATIONS: Pregnancy, lactation, concomitant use with MAOIs, hypersensitivity to venlafaxine or other components, patients aged below 18 years. PRECAUTIONS: Use with caution in patients with myocardial infarction, unstable heart disease, renal or hepatic impairment, or a history of epilepsy (discontinue in event of seizure). Patients should not drive or operate machinery if their ability to do so is

impaired. Possibility of postural hypotension (especially in the elderly). Women of child-bearing potential should use contraception. Prescribe smallest quantity of tablets according to good patient management. Monitor blood pressure with doses >200mg/day. Advise patients to notify their doctor should an allergy develop or if they become or intend to become pregnant. Use with caution in patients taking other CNS-active drugs or in the elderly or hepatically-impaired patients taking cimetidine. Patients with a history of drug abuse should be monitored carefully. Not recommended in severe renal or severe hepatic impairment. INTERACTIONS: MAOIs: do not use Efexor in combination with MAOIs or within 14 days of stopping MAOI treatment. Allow 7 days after stopping Efexor before starting a MAOI. SIDE-EFFECTS: Nausea, headache, insomnia, somnolence, dry mouth, dizziness, constipation, asthenia, sweating, nervousness, anorexia, dyspepsia, abdominal pain, anxiety, impotence, abnormality of accommodation,

vasodilation, vomiting, tremor, paraesthesia, abnormal ejaculation/orgasm, chills, hypertension, palpitation, weight gain, agitation, decreased libido, rise in blood pressure, postural hypotension, reversible increases in liver enzymes, slight increase in serum cholesterol. BASIC NHS PRICE: 37.5mg tablet (PL 0011/0199) – Calendar pack of 56 tablets: £23.97. 50mg tablet (PL 0011/0200) – Blister pack of 42 tablets: £23.97. 75mg tablet (PL 0011/0201) – Calendar pack of 56 tablets: £39.97. LEGAL CATEGORY: POM. Further information is available upon request. PRODUCT LICENCE HOLDER: Wyeth Laboratories (John Wyeth & Brother Limited), Taplow, Maidenhead, Berkshire SL6 0PH. REFERENCES: 1. Clerc GE *et al.* *Int Clin Psychopharmacol* 1994; 9: 139-142. 2. Kalus O, Asnis GH, van Praag HM, *Psychiatric Annals* 1989; 19: 348-353. 3. Data on file, Medical Affairs Department, Wyeth-Ayerst International Inc. Date of Preparation: December 1995. Code: 2773520/09/95. * trade marks.

After two neuroleptics had failed
Clozaril got to work...



...so did Steve

How long should you wait?



Proven efficacy in treatment-resistant schizophrenia

For prescribing information see adjacent page